Jaiswal N, Malik K U
Department of Pharmacology, University of Tennessee, Memphis 38163.
Prostaglandins. 1990 Mar;39(3):267-80. doi: 10.1016/0090-6980(90)90046-x.
This study was conducted to investigate the subtypes of muscarinic receptors involved in the action of cholinergic agents on prostacyclin synthesis in the rabbit aorta. Prostacyclin production measured as 6-keto-PGF1 alpha was assessed after exposing the aortic rings to different cholinergic agents. Acetylcholine (ACh) (M1 and M2 agonist) (1-10 microM) and arecaidine proparagyl ester (APE) (M2 selective agonist) (1-10 microM) enhanced 6-keto-PGF1 alpha output in a concentration-dependent manner. A selective M1 receptor agonist, McN-A-343, at 1 microM-1 mM did not alter 6-keto-PGF1 alpha output. ACh- and APE induced increases in 6-keto-PGF1 alpha output were attenuated by the M1/M2 antagonist atropine (0.1 microM), M2 alpha antagonist (AF-DX 116), (0.1-1.0 microM), and by selective M2 beta antagonist, hexahydro-sila-difendiol (HHSiD) (0.1-1.0 microM), but not by the M1 antagonist pirenzepine (1.0 microM). 6-Keto-PGF1 alpha output elicited by ACh- or APE was not altered by the adrenergic receptor antagonists phentolamine and propranolol or by the nicotinic receptor blocker hexamethonium. Similarly, the arachidonic acid- or norepinephrine induced 6-keto-PGF1 alpha accumulation was not altered by these muscarinic receptor antagonists. Indomethacin, a cyclooxygenase inhibitor, prevented arachidonic acid, ACh- or APE induced 6-keto-PGF1 alpha output. Removal of the endothelium abolished the production of 6-keto-PGF1 alpha elicited by ACh, APE, bradykinin, and calcium ionophore A 23187, but not that induced by angiotensin II, K+ or norepinephrine. These data suggest that vascular prostaglandin generation elicited by cholinergic agonists is mediated via activation of M2 alpha and M2 beta but not M1 muscarinic receptors, which are most likely located on the endothelium.
本研究旨在探究参与胆碱能药物对兔主动脉前列环素合成作用的毒蕈碱受体亚型。在将主动脉环暴露于不同胆碱能药物后,评估以6-酮-前列环素F1α衡量的前列环素生成情况。乙酰胆碱(ACh)(M1和M2激动剂)(1 - 10微摩尔)和槟榔次碱丙炔酯(APE)(M2选择性激动剂)(1 - 10微摩尔)以浓度依赖方式增强6-酮-前列环素F1α的释放量。选择性M1受体激动剂McN-A-343,在1微摩尔至1毫摩尔浓度下未改变6-酮-前列环素F1α的释放量。ACh和APE诱导的6-酮-前列环素F1α释放量增加被M1/M2拮抗剂阿托品(0.1微摩尔)、M2α拮抗剂(AF-DX 116)(0.1 - 1.0微摩尔)以及选择性M2β拮抗剂六氢硅二苯二醇(HHSiD)(0.1 - 1.0微摩尔)减弱,但未被M1拮抗剂哌仑西平(1.0微摩尔)减弱。ACh或APE引发的6-酮-前列环素F1α释放量未被肾上腺素能受体拮抗剂酚妥拉明和普萘洛尔或烟碱受体阻滞剂六甲铵改变。同样,花生四烯酸或去甲肾上腺素诱导的6-酮-前列环素F1α积累未被这些毒蕈碱受体拮抗剂改变。环氧化酶抑制剂吲哚美辛可抑制花生四烯酸、ACh或APE诱导的6-酮-前列环素F1α释放。去除内皮可消除ACh、APE、缓激肽和钙离子载体A 23187引发的6-酮-前列环素F1α生成,但不影响血管紧张素II、钾离子或去甲肾上腺素诱导的生成。这些数据表明,胆碱能激动剂引发的血管前列腺素生成是通过激活M2α和M2β而非M1毒蕈碱受体介导的,这些受体很可能位于内皮细胞上。